BioCentury | Nov 10, 2020
Product Development

Pfizer & Biogen: The good, the bAD and what’s next

COVID-19 vaccine data from Pfizer and BioNTech have set a high bar for what could be a rapid wave of readouts from other companies developing vaccines accelerated by surges in case counts. In the latest...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Warp Speed’s Slaoui expects two COVID-19 vaccines this year, rebuts Sen. Warren

Two COVID-19 vaccines and two drugs that reduce mortality from the disease will be authorized by the end of 2020, Moncef Slaoui, chief scientific adviser to Operation Warp Speed, predicted in an interview...
BioCentury | May 16, 2020
Politics, Policy & Law

Slaoui confident ‘few hundred million’ COVID-19 vaccine doses will be available by year-end

Moncef Slaoui, the former GSK executive named chief scientist of the COVID-19 vaccine acceleration program, said he has “seen early data from a clinical trial” that gave him confidence “that we will be able to...
BioCentury | Aug 29, 2019
Politics & Policy

Clock ticking on Sharpless' term as acting FDA commissioner

...AlloVir. Giroir has been a board member of biomedical companies BrainCheck Inc. (Houston, Texas) and Esperance Pharmaceuticals Inc....
...Health in Dallas; and professor at the University of Texas Southwestern Medical Center. Steve Usdin, Washington Editor AlloVir Esperance Pharmaceuticals Inc. Texas...
BioCentury | Jun 15, 2015
Clinical News

EP-100: Phase II data

...paclitaxel led to an ORR, the primary endpoint, of 34.8% vs. 33.3% for paclitaxel alone. Esperance...
...>3 months. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Esperance Pharmaceuticals Inc....
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

...and an undisclosed amount in June 2011 in a series B round for cancer play Esperance Pharmaceuticals Inc....
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...with Cancer Research Technology Ltd. to develop ADCs. A third company developing improved payloads is Esperance Pharmaceuticals Inc....
...N.J. City of Hope , Duarte, Calif. Endo Health Solutions Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Esperance Pharmaceuticals Inc....
...a mAb Preclin Improved payloads ADC Therapeutics S.a.r.l. Pyrrolobenzodiazepine (PDB) payloads that cross-link DNA Preclin Esperance Pharmaceuticals Inc....
BioCentury | Jun 11, 2012
Clinical News

EP-100: Phase I data

...month, Esperance began the Phase II ESP2011-002 trial of EP-100 to treat advanced ovarian cancer. Esperance Pharmaceuticals Inc....
BioCentury | May 28, 2012
Clinical News

EP-100: Phase II started

...includes a run-in period in 5-8 patients to confirm the maximum safe dose of EP-100. Esperance Pharmaceuticals Inc....
BioCentury | Jun 13, 2011
Financial News

Esperance completes venture financing

...Fund; Themelios Ventures Partners; Research Corp. Technologies; Advantage Capital Partners; existing investors; new investors Note: Esperance...
Items per page:
1 - 10 of 17
BioCentury | Nov 10, 2020
Product Development

Pfizer & Biogen: The good, the bAD and what’s next

COVID-19 vaccine data from Pfizer and BioNTech have set a high bar for what could be a rapid wave of readouts from other companies developing vaccines accelerated by surges in case counts. In the latest...
BioCentury | Sep 26, 2020
Politics, Policy & Law

Warp Speed’s Slaoui expects two COVID-19 vaccines this year, rebuts Sen. Warren

Two COVID-19 vaccines and two drugs that reduce mortality from the disease will be authorized by the end of 2020, Moncef Slaoui, chief scientific adviser to Operation Warp Speed, predicted in an interview...
BioCentury | May 16, 2020
Politics, Policy & Law

Slaoui confident ‘few hundred million’ COVID-19 vaccine doses will be available by year-end

Moncef Slaoui, the former GSK executive named chief scientist of the COVID-19 vaccine acceleration program, said he has “seen early data from a clinical trial” that gave him confidence “that we will be able to...
BioCentury | Aug 29, 2019
Politics & Policy

Clock ticking on Sharpless' term as acting FDA commissioner

...AlloVir. Giroir has been a board member of biomedical companies BrainCheck Inc. (Houston, Texas) and Esperance Pharmaceuticals Inc....
...Health in Dallas; and professor at the University of Texas Southwestern Medical Center. Steve Usdin, Washington Editor AlloVir Esperance Pharmaceuticals Inc. Texas...
BioCentury | Jun 15, 2015
Clinical News

EP-100: Phase II data

...paclitaxel led to an ORR, the primary endpoint, of 34.8% vs. 33.3% for paclitaxel alone. Esperance...
...>3 months. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Esperance Pharmaceuticals Inc....
BioCentury | Jan 20, 2014
Finance

Genzyme Ventures reboot

...and an undisclosed amount in June 2011 in a series B round for cancer play Esperance Pharmaceuticals Inc....
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

...with Cancer Research Technology Ltd. to develop ADCs. A third company developing improved payloads is Esperance Pharmaceuticals Inc....
...N.J. City of Hope , Duarte, Calif. Endo Health Solutions Inc. (NASDAQ:ENDP), Chadds Ford, Pa. Esperance Pharmaceuticals Inc....
...a mAb Preclin Improved payloads ADC Therapeutics S.a.r.l. Pyrrolobenzodiazepine (PDB) payloads that cross-link DNA Preclin Esperance Pharmaceuticals Inc....
BioCentury | Jun 11, 2012
Clinical News

EP-100: Phase I data

...month, Esperance began the Phase II ESP2011-002 trial of EP-100 to treat advanced ovarian cancer. Esperance Pharmaceuticals Inc....
BioCentury | May 28, 2012
Clinical News

EP-100: Phase II started

...includes a run-in period in 5-8 patients to confirm the maximum safe dose of EP-100. Esperance Pharmaceuticals Inc....
BioCentury | Jun 13, 2011
Financial News

Esperance completes venture financing

...Fund; Themelios Ventures Partners; Research Corp. Technologies; Advantage Capital Partners; existing investors; new investors Note: Esperance...
Items per page:
1 - 10 of 17